The development of biosimilars involves a rigorous process to ensure they are highly similar to the original biologic. This includes extensive analytical testing, preclinical studies, and clinical trials. The aim is to demonstrate that there are no clinically meaningful differences in terms of safety, purity, and potency between the biosimilar and the reference product. Regulatory agencies such as the FDA or EMA require comprehensive evidence before approving a biosimilar for clinical use.
